Cancer vaccine Theratope - Biomira

Drug Profile

Cancer vaccine Theratope - Biomira

Alternative Names: Theratope

Latest Information Update: 31 May 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biomira
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Breast cancer; Colorectal cancer
  • No development reported Adenocarcinoma; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 30 Jul 2004 Theratope® is available for licensing (
  • 30 Jul 2004 Biomira has completed enrolment in a phase II trial for breast cancer in the USA
  • 07 Jun 2004 Merck KGaA has terminated its licence for Theratope®
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top